Karo Bio : Positive Results in First Clinical Study with Anti Diabetes Compound KB3305

April 17, 2008 - Karo Bio’s compound, KB3305, for treatment of type 2 diabetes, shows robust and predictable pharmacokinetics and the subjects are well exposed without serious adverse events in the first phase I clinical study. The incidence of type 2 diabetes is increasing rapidly and there is a need for improved pharmaceuticals with new mechanisms of action. KB3305 is a first in class liver selective glucocorticoid antagonist that has shown excellent efficacy and safety in several preclinical models for type 2 diabetes... Karo Bio's Press Release -